Peru Biocompatibility and Sterilization Validation: ISO 10993 Evidence in the Dossier

Regulatory information verified as of October 29, 2026

1. Key takeaways

Biocompatibility in Peru is not a standalone submission item in the Class III/IV dossier. It is absorbed into the evidence layer of item 4, the technical report, and the Essential Principles list, the Principios Esenciales de Seguridad y Desempeño. Sterile devices, in turn, present their evidence separately through item 9, the sterilization process validation report. The review criterion common to both is the same: what must be demonstrated is the set of conditions under which the conclusion holds, not that some sample passed once. Files that present a passing result without defining the conditions of that result, the contact duration behind a biocompatibility claim, or the load configuration behind a sterility claim, are read as incomplete even when every individual test report looks conforming on its face.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight 1: The depth of the biological evaluation is determined by the nature and duration of contact, not by the product category.

The 18 classification rules of D.S. N° 003-2020-SA, published on 2020-02-06, take the route of invasion, the contact site, and the duration of contact as their core variables. Two devices made of the same material can land on different biological evaluation requirements solely because their contact durations differ, whether transient, short term, long term, or permanent. The mechanical implication is direct: a company that derives evaluation depth from the habit that this product category has always been evaluated this way will get the class wrong. The correct order is to determine the class from the classification rules first, and then derive the evaluation endpoints backward from the class and the contact profile. The ISO 10993 series serves here as the route for determining evaluation endpoints and test methods, not as a fixed list of mandatory tests.

Insight 2: The sterilization process validation report and a per-batch release test are two different things, and mixing them invalidates item 9.

Sterility cannot be proven by sampling the finished product, because the sampling act itself destroys the sterile state, and the probability of a sampling plan cannot represent the distribution within a batch. What the validation report must demonstrate is that the process repeatably reaches the defined sterility assurance level under routine operating conditions, which is why its argument structure runs through installation qualification, operational qualification, performance qualification, and periodic requalification. Two failures recur: submitting a product sterility test report in place of the validation report, and validating the most favorable load while routine production uses a different configuration, so that the validated conditions and the actual conditions no longer match.

Insight 3: A chain between biocompatibility and sterilization validation must be closed, and it is the sterilant residues.

Different sterilization methods leave different residues, as in the control of ethylene oxide residuals. The sterilization process parameters of item 9 directly determine the identity and initial levels of the residues, and these are precisely an input to the biological evaluation. The two documents are most often disconnected when written by different teams: the process side sets parameters according to process capability, the biology side evaluates against reference limits, and the two never meet, leaving a product that is achievable in the process but unsustainable toxicologically. GRZAN requires in its projects that the biocompatibility evaluation inputs be updated in step once the process is frozen.

Insight 4: Reusable devices carry an additional boundary, the number of permitted reprocessing cycles.

Unless the cleaning, disinfection, and resterilization procedures are supported by data up to a maximum number of cycles, the risk assessment of a reusable device remains incomplete, and the reprocessing information in the instructions for use, the Instrucciones de Uso or IFU, must be stated on the same basis.

4. Practical recommendations

1. Determine the class first under the 18 classification rules of D.S. N° 003-2020-SA, then derive the biological evaluation endpoints backward.
2. Build an evaluation input table listing materials, contact site, contact duration, and sterilant residues as the premise of the toxicological assessment.
3. Write item 9 in the structure of installation, operational, and performance qualification plus periodic requalification; a single-batch test report is never an acceptable substitute.
4. Keep routine production loads and monitoring consistent with the validated conditions and state that consistency in the report.
5. For reusable devices, define the upper limit of reprocessing cycles and state it in the IFU at the same time.
6. For sterile supplies, check the BPM manual scope of R.M. N° 204-2000-SA/DM in parallel.

5. Verification checklist

□ The class has been determined under the 18 classification rules and evaluation depth derived from the class

□ The biological evaluation inputs include materials, contact pathway, duration, and sterilant residues

□ Item 9 is a sterilization process validation report, not a single-batch sterility test report

□ The consistency between worst-case load and routine monitoring is explained

□ Residue levels and release criteria for ethylene oxide and other sterilization methods are justified

□ The reprocessing cycle limit of reusable devices is stated in the IFU at the same time

Regulatory information verified as of October 29, 2026.

*GRZAN Regulatory Team*

GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives, covering biocompatibility evaluation, ISO 10993 endpoint selection, sterilization validation review, and deficiency response. For inquiries, contact info@grzanglobal.com.